SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study July 31, 2019 - NASDAQ Companies 0 » View More News for July 31, 2019
